Enliven therapeutics announces positive proof of concept data from phase 1 clinical trial of elvn-001 in chronic myeloid leukemia

Achieved initial cumulative mmr rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent phase 1 trials of approved bcr::abl1 tkis

ELVN Ratings Summary

ELVN Quant Ranking